Skip to Content

'
Agop Y. Bedikian, M.D.

Present Title & Affiliation

Primary Appointment

Professor And Deputy Director of the Skin Center, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Internist, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1971 American University of Beirut, Beirut, Lebanon, MD, Medicine
1967 University of Beirut, N/A, Lebanon, BS, Bachelor of Science

Postgraduate Training

1975-1977 Clinical Fellowship, Medical Oncology, The University of Texas System Cancer Center, Houston, TX
1973-1975 Clinical Residency, Oncology, Barnes Hospital, St. Louis, MO

Board Certifications

6/1979 American Board of Medical Oncology
6/1977 American Board of Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles
1. Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther 8(6):839-44, 2008. PMID: 18476795.
2. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos N, Kim K, Hwu WJ, McIntyre S, Hwu P. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 26(6):624-33, 2008. PMID: 18584354.
3. Bedikian AY, Johnson MM, Warneke CL. McIntyre S, Papadopoulos N, Hwu WJ, Kim K, Hwu P. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol 5(2):201 - 7, 2008. PMID: 1856939.
4. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24(29):4738-45, 10/2006. e-Pub 9/2006. PMID: 16966688.
5. Bedikian AY, Vardeleon A, Smith T, Campbell S, Namdari R. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol 46(7):727-37, 7/2006. PMID: 16809798.
6. Kim K, Bedikian AY, Camacho LH, Papadopoulos NE, McCullough C. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 104(8):1687-92, 10/2005. PMID: 16130126.
7. Gogas H, Bafaloukos D, Bedikian AY. The role of taxanes in the treatment of metastatic melanoma. Melanoma Res 14(5):415-20, 10/2004. PMID: 15457099.
8. Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer 101(3):596-603, 8/2004. PMID: 15274073.
9. Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 14(1):63-6, 2/2004. PMID: 15091196.
10. Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res 13(3):303-6, 6/2003. PMID: 12777987.
11. Eton O, Rosenblum MG, Legha SS, Zhang W, Jo East M, Bedikian A, Papadopoulos N, Buzaid A, Benjamin RS. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer 95(1):127-34, 7/2002. PMID: 12115326.
12. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20(8):2045-52, 4/2002. PMID: 11956264.
13. Ellerhorst JA, Bedikian AY, Smith TM, Papadopoulos NE, Plager C, Eton O. Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anticancer Drugs 13(2):169-72, 2/2002. PMID: 11901310.

Invited Articles
1. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int'l Ophthalmol Clin 46(1):151-166, 2006.

Abstracts
1. Bedikian AY, Gonzalez R, Richards J, Atkins MB, Whitman E, Morse MA, Amatruda T, Hutchins L, Thompson J, Galanis E. A phase II study of high-dose allovectin-7 in patients with advanced metastatic melanoma. Proc. Am Soc Clin Oncol 22:720 (#2897), 2003.

Book Chapters
1. McGary EC, Bedikian AY, Rapini RP. Malignant Melanoma: Biology, Diagnosis and Management. Chapter M. D. Anderson Manual of Medical Oncology. In: The M.D. Anderson Manual of Medical Oncology. 32. McGraw-Hill: New York, NY, 855-877, 2006.

Last updated: 9/8/2009